157 related articles for article (PubMed ID: 20307650)
1. N-acetyl-L-methionyl-L-Dopa-methyl ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity.
Minelli A; Conte C; Prudenzi E; Cacciatore I; Cornacchia C; Taha E; Pinnen F
Free Radic Biol Med; 2010 Jul; 49(1):31-9. PubMed ID: 20307650
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Kostrzewa RM; Kostrzewa JP; Brus R
Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
[TBL] [Abstract][Full Text] [Related]
3. Protection of dopaminergic neurons in primary culture by lisuride.
Gille G; Rausch WD; Hung ST; Moldzio R; Ngyuen A; Janetzky B; Engfer A; Reichmann H
J Neural Transm (Vienna); 2002 Feb; 109(2):157-69. PubMed ID: 12075855
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of l-DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal-enriched cultures from parkin knockout and wild-type mice.
Casarejos MJ; Solano RM; Menéndez J; Rodríguez-Navarro JA; Correa C; García de Yébenes J; Mena MA
J Neurochem; 2005 Aug; 94(4):1005-14. PubMed ID: 16000163
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
6. Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity.
Abdin AA; Sarhan NI
Neurosci Res; 2011 Dec; 71(4):387-95. PubMed ID: 21889550
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson's animal model.
Minelli A; Conte C; Cacciatore I; Cornacchia C; Pinnen F
Amino Acids; 2012 Sep; 43(3):1359-67. PubMed ID: 22218995
[TBL] [Abstract][Full Text] [Related]
8. Levodopa: effect on cell death and the natural history of Parkinson's disease.
Olanow CW
Mov Disord; 2015 Jan; 30(1):37-44. PubMed ID: 25502620
[TBL] [Abstract][Full Text] [Related]
9. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
[TBL] [Abstract][Full Text] [Related]
10. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
Billings JL; Gordon SL; Rawling T; Doble PA; Bush AI; Adlard PA; Finkelstein DI; Hare DJ
J Neurochem; 2019 Jul; 150(1):88-106. PubMed ID: 30716176
[TBL] [Abstract][Full Text] [Related]
11. L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease.
Cooper DR; Marrel C; Testa B; van de Waterbeemd H; Quinn N; Jenner P; Marsden CD
Clin Neuropharmacol; 1984; 7(1):89-98. PubMed ID: 6704979
[TBL] [Abstract][Full Text] [Related]
12. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress.
Han SK; Mytilineou C; Cohen G
J Neurochem; 1996 Feb; 66(2):501-10. PubMed ID: 8592119
[TBL] [Abstract][Full Text] [Related]
13. L-dopa therapy for Parkinson's disease: past, present, and future.
Nagatsua T; Sawadab M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
[TBL] [Abstract][Full Text] [Related]
14. A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy.
Colamartino M; Duranti G; Ceci R; Sabatini S; Testa A; Cozzi R
Toxicol In Vitro; 2018 Mar; 47():1-7. PubMed ID: 29080800
[TBL] [Abstract][Full Text] [Related]
15. Peculiarities of L: -DOPA treatment of Parkinson's disease.
Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
[TBL] [Abstract][Full Text] [Related]
16. Metabolic inhibition enhances selective toxicity of L-DOPA toward mesencephalic dopamine neurons in vitro.
Nakao N; Nakai K; Itakura T
Brain Res; 1997 Nov; 777(1-2):202-9. PubMed ID: 9449429
[TBL] [Abstract][Full Text] [Related]
17. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
Chiu WH; Carlsson T; Depboylu C; Höglinger GU; Oertel WH; Ries V
Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466
[TBL] [Abstract][Full Text] [Related]
18. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
19. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
Lees AJ; Tolosa E; Olanow CW
Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
[TBL] [Abstract][Full Text] [Related]
20. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
St-Hilaire M; Bourhis E; Lévesque D; Rouillard C
Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
